SRDX
Surmodics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
ample liquidity
High Gross Profit Margin
Net Income Plunges
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SRDX
Surmodics, Inc.
A leading provider of medical device and in vitro diagnostic technologies to the healthcare industry
Healthcare Equipment and Supplies
Invalid Date
03/06/1998
NASDAQ Stock Exchange
389
09-30
Common stock
9924 West 74th Street, Eden Prairie, Minnesota 55344
--
Surmodics, Inc., is a leading supplier of intravascular medical devices for in vitro diagnostic immunoassay tests and microarrays, as well as performance coating technologies for chemical and biological components. The company develops and commercializes highly differentiated vascular interventional medical devices designed to meet unmet clinical needs and designed for the most demanding requirements. This key growth strategy leverages the company's expertise in proprietary surface modification and drug delivery coating technologies, as well as a combination of its equipment design, development and manufacturing capabilities. The company's mission is to improve the detection and treatment of diseases.
Company Financials
EPS
SRDX has released its 2025 Q2 earnings. EPS was reported at -0.13, versus the expected -0.11, missing expectations. The chart below visualizes how SRDX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SRDX has released its 2025 Q2 earnings report, with revenue of 28.09M, reflecting a YoY change of -12.12%, and net profit of -5.21M, showing a YoY change of -2208.91%. The Sankey diagram below clearly presents SRDX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
